With a market cap of $138.2 billion, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines worldwide. Its portfolio spans key therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, with well-known products such as Opdivo, Eliquis, Revlimid, and Yervoy.
Companies valued at $10 billion or more are generally classified as "large-cap" stocks, and Bristol-Myers Squibb fits this criterion perfectly. The company serves patients through a broad commercial network that includes wholesalers, distributors, specialty pharmacies, hospitals, clinics, and government agencies.
Nvidia CEO Jensen Huang Says His $3.5 Billion MediaTek Deal Is 'Not Circular' Because 'They Do Their Own Business'
Strategy's Strategy Appears to Have Failed, and the Outlook of MSTR Stock Is Unfavorable
A Potential ***** eX Deal Could Meaningfully Accelerate Growth for Technip Stock
#company #bristol #squibb #Stock
Companies valued at $10 billion or more are generally classified as "large-cap" stocks, and Bristol-Myers Squibb fits this criterion perfectly. The company serves patients through a broad commercial network that includes wholesalers, distributors, specialty pharmacies, hospitals, clinics, and government agencies.
Nvidia CEO Jensen Huang Says His $3.5 Billion MediaTek Deal Is 'Not Circular' Because 'They Do Their Own Business'
Strategy's Strategy Appears to Have Failed, and the Outlook of MSTR Stock Is Unfavorable
A Potential ***** eX Deal Could Meaningfully Accelerate Growth for Technip Stock
#company #bristol #squibb #Stock
3 days ago
